The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

被引：0

作者：

Giai, Valentina ^{[1
]}

Stagno, Fabio ^{[2
]}

Rosso, Tiziana ^{[3
,4
]}

Castagnetti, Fausto ^{[5
,6
]}

Capodanno, Isabella ^{[7
]}

Bonifacio, Massimiliano ^{[8
,9
]}

Tiribelli, Mario ^{[10
]}

Galimberti, Sara ^{[11
]}

Bocchia, Monica ^{[12
]}

Gozzini, Antonella ^{[13
]}

Caocci, Giovanni ^{[14
]}

Patriarca, Andrea ^{[15
]}

Lanzarone, Giuseppe ^{[16
]}

Guella, Anna ^{[17
]}

Sora, Federica ^{[18
]}

Luciano, Luigiana ^{[19
]}

Scortechini, Anna Rita ^{[20
]}

di Renzo, Nicola ^{[21
]}

Musto, Pellegrino ^{[22
,23
]}

Pastore, Domenico ^{[24
]}

Maggi, Alessandro ^{[25
]}

Fava, Carmen ^{[26
,27
]}

Pavone, Vincenzo

Fozza, Claudio ^{[28
,29
]}

Spinosa, Giuseppina ^{[30
]}

Carella, Angelo Michele ^{[31
]}

Tarantini, Giuseppe ^{[32
]}

Martino, Bruno ^{[33
]}

Pizzuti, Michele ^{[34
]}

Mannarella, Clara ^{[35
]}

Saccona, Fabio

Rosti, Gianantonio ^{[36
]}

Pregno, Patrizia ^{[37
]}

Breccia, Massimo ^{[38
]}

Pane, Fabrizio ^{[3
,4
,39
]}

Ciccone, Giovannino ^{[40
,41
]}

Specchia, Giorgina ^{[42
]}

Saglio, Giuseppe ^{[43
]}

机构：

[1] Citta Salute Sci, Div Hematol, Turin, Italy

[2] AOU Policlin Rodolico San Marco, Div Hematol & Bone Marrow Transplant, Catania, Italy

[3] Citta Salute Sci, Clin Epidemiol Unit, Turin, Italy

[4] Citta Salute Sci, CPO Piemonte, Turin, Italy

[5] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[6] IRCCS Azienda Osped Univ Bologna, Hematol Unit, Bologna, Italy

[7] Azienda Unita Sanitaria Locale IRCCS, Hematol Unit, Reggio Emilia, Italy

[8] Azienda Osped Univ Integrata Verona, Dept Med, Verona, Italy

[9] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med, Hematol Area, Verona, Italy

[10] Univ Udine, Div Hematol & BMT, Dept Med Area, Udine, Italy

[11] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy

[12] Univ Siena, Azienda Osped Univ Senese, Hematol, Siena, Italy

[13] Univ Florence, Hematol, AOU Careggi, Florence, Italy

[14] Univ Cagliari, Businco Hosp, Dept Med Sci & Publ Hlth, Cagliari, Italy

[15] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[16] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[17] APSS Trento, Santa Chiara Hosp, Hematol Unit, Trento, Italy

[18] Univ Cattolica Sacro Cuore, Inst Hematol, Rome, Italy

[19] Univ Naples Federico II, Hematol Unit, Naples, Italy

[20] Polytech Univ Marche, Div Hematol, Dept Mol & Clin Sci, Ancona, Italy

[21] Osped V Fazzi, Haematol, Lecce, Italy

[22] Aldo Moro Univ, Sch Med, Dept Precis & Regenerat Med & Ionian Area, Haematl, Bari, Italy

[23] AOU Consorziale Policlin, Hematol & Stem Cell Transplantat Unit, Bari, Italy

[24] Osped A Perrino, Haematol, Brindisi, Italy

[25] Osped SG Moscati, Haematol, Taranto, Italy

[26] Mauriziano Hosp, Hematol, Turin, Italy

[27] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[28] Azienda C Panico, Hematol Unit, Tricase, Italy

[29] Univ Sassari, Azienda Osped Univ Sassari, Hematol Unit, Sassari, Italy

[30] Policlin Riuniti Osped Univ, Hematol Unit, Foggia, Italy

[31] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy

[32] Osped Mons Dimiccoli, Haematol, Barletta, Italy

[33] Grande Osped Metropolitano Bianchi Melacrino More, Hematol Unit, Reggio Di Calabria, Italy

[34] San Carlo Reg Hosp, Dept Oncohematol, Potenza, Italy

[35] Osped Madonna Grazie, Hematol Unit, Matera, Italy

[36] IRST IRCCS Dino Amadori, Med Oncol Unit, Meldola, FC, Italy

[37] Citta Salute Sci, Div Hematol, Turin, Italy

[38] Hematol Sapienza Univ, Dept Translat & Precis Med, Rome, Italy

[39] Azienda Osped Univ Federico II, Dipartimento Med Clin & Chirurgia, UOC Ematol & Trapianti Midollo, Naples, Italy

[40] AOU Citta Salute & Sci, SSD Epidemiol Clin & Valutativa, Turin, Italy

[41] CPO Piemonte, Turin, Italy

[42] Univ Bari, Hematol, Bari, Italy

[43] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182981

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 36 条

[1] First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice
Cortes, Jorge
ONCOLOGY-NEW YORK, 2013, 27 (08): : 781 - 781
[2] First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Vener, Claudia
Banzi, Rita
Ambrogi, Federico
Ferrero, Annalisa
Saglio, Giuseppe
Pravettoni, Gabriella
Sant, Milena
BLOOD ADVANCES, 2020, 4 (12) : 2723 - 2735
[3] THIRD-LINE TREATMENT WITH 2ND GENERATION TYROSINE KINASE INHIBITORS (TKIS) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED TWO PRIOR TKIS: A SINGLE CENTER EXPERIENCE OF 21 PATIENTS
Salihoglu, A.
Eskazan, A. E.
Suzan, V.
Savci, S.
Erdogan, I.
Berk, S.
Yalniz, F. F.
Elverdi, T.
Ar, M. C.
Aydin, S. Ongoren
Baslar, Z.
Aydin, Y.
Tuzuner, N.
Ozbek, U.
Soysal, T.
HAEMATOLOGICA, 2015, 100 : 696 - 697
[4] ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients
Tiribelli, Mario
Di Giusto, Sara
Toffoletti, Eleonora
Griguolo, Davide
Penna, Domenico
Maccari, Giorgia
Medeot, Marta
Fanin, Renato
Damiani, Daniela
BLOOD, 2017, 130
[5] IMATINIB FIRST-LINE WITH SWITCH TO 2ND GENERATION TYROSINE KINASE INHIBITORS IN CASE OF FAILURE OR TOXICITY: REAL-LIFE DATA FROM A POPULATION-BASED REGISTRY OF BCR-ABL1+CML PATIENTS
Castagnetti, F.
Stagno, F.
de Vivo, A.
Spitalieri, A.
Gugliotta, G.
Fabbiano, F.
Capodanno, I.
Mannina, D.
Salvucci, M.
Antolino, A.
Marasca, R.
Musso, M.
Crugnola, M.
Consoli, U.
Trabacchi, E.
Musolino, C.
Cavazzini, F.
Longo, G.
Tosi, P.
Cardinale, G.
Soverini, S.
Rizzo, M.
Martinelli, G.
Cavo, M.
Vigneri, P.
Rosti, G.
Di Raimondo, F.
Baccarani, M.
HAEMATOLOGICA, 2016, 101 : 456 - 457
[6] Evaluation of Peroxiredoxins (PRDX1, PRDX2 and PRDX6) Expression in Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib in First Line
Mascarenhas, Cintia
Woldmar, Lara
Almeida, Maria Helena
Andrade, Rosangela Vieira
Cunha, Anderson Ferreira
De Souza, Carmino A.
BLOOD, 2014, 124 (21)
[7] Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line
Casado Montero, Luis Felipe
Garcia-Ormena, Nuria
Encinas, Manuel Perez
Osorio-Prendes, Santiago
Ferrer Marin, Francisca
Sagues, Miguel
Garcia-Gutierrez, Valentin
Marco De Lucas, Fernando
Boque, Concepcion
Noya, Soledad
Gomez Casares, Maria Teresa
Estrada, Natalia
Angeles Goni, Maria
Ramirez Payer, Angel
Jose Requena, Maria
Lakhwani, Sunil
Andrade Campos, Marcio Miguel
De las Heras, Natalia
Angeles Foncillas, Maria
Luis Steegmann, Juan
BLOOD, 2022, 140 : 3908 - 3910
[8] Survival outcomes for patients (Pts) with chronic myeloid leukemia (CML) with clonal evolution (CE) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure
Verma, Dushyant
Kantarjian, Hagop
Estrov, Zeev
Garcia-Mancro, Guillermo
Koller, Charles
Borthakur, Gautam
Cortes, Jorge
BLOOD, 2007, 110 (11) : 866A - 867A
[9] MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients
Agrawal, M.
Erben, P.
Hanfstein, B.
Popa, J.
Hofmann, W-K
Leitner, A.
Hochhaus, A.
Mueller, M. C.
ONKOLOGIE, 2010, 33 : 144 - 144
[10] MDR1 expression serves as a pharmacogenetic marker for the prediction of molecular, cytogenetic and clinical outcome on 2nd line nilotinib therapy in imatinib-resistant CML patients
Agrawal, M.
Erben, P.
Hanfstein, B.
Popa, J.
Hofmann, W. K.
Leitner, A.
Hochhaus, A.
Mueller, M. C.
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 : 86 - 86

← 1 2 3 4 →